Moderna, Inc. $MRNA Shares Acquired by ProShare Advisors LLC

ProShare Advisors LLC boosted its stake in Moderna, Inc. (NASDAQ:MRNA) by 6.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 74,898 shares of the company’s stock after purchasing an additional 4,277 shares during the quarter. ProShare Advisors LLC’s holdings in Moderna were worth $14,423,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Vise Technologies Inc. raised its holdings in shares of Moderna by 63.0% during the third quarter. Vise Technologies Inc. now owns 8,879 shares of the company’s stock valued at $1,710,000 after purchasing an additional 3,432 shares during the period. Blue Fin Capital Inc. acquired a new stake in shares of Moderna in the 3rd quarter valued at about $432,000. MGO One Seven LLC grew its stake in shares of Moderna by 8.7% in the 3rd quarter. MGO One Seven LLC now owns 3,428 shares of the company’s stock valued at $660,000 after buying an additional 275 shares during the period. Americana Partners LLC acquired a new stake in shares of Moderna in the 3rd quarter valued at about $1,482,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al increased its position in Moderna by 3.8% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 65,750 shares of the company’s stock valued at $12,661,000 after buying an additional 2,400 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 34,836 shares of Moderna stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the transaction, the chief financial officer owned 59,375 shares of the company’s stock, valued at $7,985,343.75. This trade represents a 36.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 39,145 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $220.72, for a total value of $8,640,084.40. Following the completion of the transaction, the president owned 1,636,565 shares in the company, valued at $361,222,626.80. The trade was a 2.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 197,251 shares of company stock valued at $33,875,904. Corporate insiders own 10.80% of the company’s stock.

Moderna Trading Down 0.4%

NASDAQ MRNA opened at $220.83 on Tuesday. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $184.00 and a 200 day simple moving average of $87.42. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $254.48. The firm has a market capitalization of $88.16 billion, a P/E ratio of -27.64 and a beta of 1.09.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. During the same period in the previous year, the firm earned ($2.13) EPS. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, analysts predict that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on MRNA. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Moderna in a research note on Friday, September 25th. Citigroup reiterated a “sell” rating on shares of Moderna in a report on Friday, October 23rd. Deutsche Bank Aktiengesellschaft started coverage on Moderna in a research note on Friday, August 28th. They issued a “hold” rating and a $125.00 price objective for the company. Royal Bank Of Canada restated a “sector perform” rating and set a $130.00 price objective on shares of Moderna in a report on Wednesday, August 19th. Finally, Berenberg Bank boosted their price objective on Moderna from $45.00 to $100.00 and gave the company a “hold” rating in a report on Friday, September 11th. Six analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus price target of $107.10.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.